Insulin glulisine
FDA approved · RxRapid-acting insulin analog
Also known as: Apidra, Apidra Solostar
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 117 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Insulin glulisine is a man-made version of human insulin with two small changes to its amino acid sequence that help it absorb faster after injection. Like the body's own insulin, it lowers blood sugar by helping muscle and fat cells take up glucose and by reducing glucose release from the liver. It is sold under the brand names Apidra and Apidra Solostar.
What the evidence shows
It is FDA-approved for improving blood sugar control in adults and children with diabetes mellitus, and it is backed by a large body of human research, including 124 registered trials that reach Phase 4 and about 209 published papers. Its main known risk, shared with all insulins, is low blood sugar.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
Comparative Trial Between 3 Types of Insulin Infusion Protocols
Apidra Children & Adolescents Study
Normal Versus Dual Wave Insulin Bolus for High-protein Food
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.
Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes.
Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.